The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
so people lose more weight so it's about 21% weight loss at a year — fewer side effects — at least at comparable doses that seems to be because this this other drug — tepati — it has two Targets not one so so whereas whereas OIC is just — gp1 receptor Agonist tepati is a dual Agonist of glp1 and this other in that we talked about Gip
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Trizepatide activates both GLP-1 and GIP-1 receptors, leading to synergistic effects in lowering blood glucose, suppressing appetite, weight loss and cardiovascular protection (18, 19).
now sir septibite is the new kid on the Block it's a dual Agonist a Gip glp-1 receptor Agonist this has been approved also for diabetes although the outcome trial for diabetes is ongoing the surmount outcome trial but it also has been evaluated for weight loss and really showed dramatic weight loss you know up to 50 pounds in the highest dose which is really remarkable